What are the supply chain challenges associated with the commercialization of cell therapy products?

Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Jessica Carmen, Business Development Manager of Lonza Walkersville. Jessica discusses supply chain & logistical challenges associated with commercialization, the evolution of the cell therapy field and where it is headed in the next five years, advancements in technology and much more. Below is a brief excerpt from the podcast, follow the links below to access the complete podcast and transcript.

Listen to the podcast | Read the transcript 

Are there unique supply chain challenges associated with the commercialization of cell therapy products?

Yes, there are. There are many raw materials that are used in the manufacture of cell-based products that can pose a challenge when considering commercial needs, an example of which is the animal serum. Most cell types are culture-expanded in animal serums and there is a move in the field towards serum-free conditions. This is good from a supply chain and safety risk standpoint. However, most companies still employ animal serum in their processing and will need to consider the increasing costs and logistical challenges associated with the ever-increasing demand for this raw material. 


Be sure to join us at Cell Therapy Bioprocessing & Commercialization in Alexandria, VA - September 30th to October 2nd, 2015. Register before 9/4 and save $300 with the code XB15188BLOG.

Register here | Download the agenda

Share this article with your social network, just click below to share now!

Share |

Unlock the Key to Advancing Immuno-Oncology

As innovations and discoveries in cancer immunotherapies progress at lightning speed, it is critical to understand the successes and challenges with current immunotherapies to separate the hype from the real opportunities. IBC's Immuno-Oncology event develops tactics for improving the efficacy and response rates with first generation immunotherapies and builds a strategy for utilizing combination therapies, t-cell therapies, and checkpoint inhibitors to propel the next wave of cancer immunotherapies.

Download the Immuno-Oncology brochure now to create your pathway for an answer to cancer: http://bit.ly/1O6tbIZ

Immuno-Oncology

Advancing the Next Generation of Cancer Immunotherapies

September 30 – October 1, 2015

Hilton Alexandria Mark Center, Alexandria, VA

Register today and explore the latest advances in Immuno-Oncology to:

Develop next generation immunotherapies by understanding recent advances made with CAR-T and T-Cell therapies, checkpoint inhibitors, cancer vaccines, and agnostic antibodies

Create a successful combination therapy strategy by gaining insights from global leaders on effective combinations

Optimize the discovery and development of your promising immunotherapies by hearing best practices and lessons learned from the first wave of cancer immunotherapies

Download the brochure for full program details: http://bit.ly/1O6tbIZ

Reserve your seat now. Use code IMMUNO15BL to get $100 off the current rate. Register today: http://bit.ly/1O6tbIZ

Best,

The Immuno-Oncology Team 2015

@ibcusa

#Immuno15

Related articles

• New Drug Combination Boosts Immune System and Manipulates Gene Activity To Slow Leukemia
• Researchers develop method to increase T cells in melanoma patients

Share this article with your social network, just click below to share now!

Share |

Create Your Own Pathway for an Answer to Cancer

As innovations and discoveries in cancer immunotherapies progress at lightning speed, it is critical to understand the successes and challenges with current immunotherapies to separate the hype from the real opportunities.

IBC's Immuno-Oncology event develops tactics for improving the efficacy and response rates with first generation immunotherapies and builds a strategy for utilizing combination therapies, t-cell therapies, and checkpoint inhibitors to propel the next wave of cancer immunotherapies.

Immuno-Oncology

Advancing the Next Generation of Cancer Immunotherapies

September 31-October 1, 2015

Hilton Alexandria Marks Center

Alexandria, Virginia

Download the Immuno-Oncology brochure now to create your pathway for an answer to cancer: http://bit.ly/1KB4Nkg

Register today and explore the latest advances in Immuno-Oncology to:

• Develop next generation immunotherapies by understanding recent advances made with CAR-T and T-Cell therapies, checkpoint inhibitors, cancer vaccines, and agnostic antibodies
• Create a successful combination therapy strategy by gaining insights from global leaders on effective combinations

Optimize the discovery and development of your promising immunotherapies by hearing best practices and lessons learned from the first wave of cancer immunotherapies.

We hope to see you this fall!

Register by June 19th and save up to $400: http://bit.ly/1KB4Nkg

Best,

The Immuno-Oncology Team

@ibcusa

Futurebiopharma.blogspot.com

Share this article with your social network, just click below to share now!

Share |

Accelerate Your Path from Concept to Product

Learn to how to apply the cost-effective and efficient strategies you need to advance your cell, gene and immunotherapies towards commercial success by attending IBC's Cell Therapy Bioprocessing & Commercialization meeting, held September 30 - October 2, 2015 in Alexandria, VA.

Secure your seat today to attend this year's meeting and learn alongside fellow developers and end-users as you collectively share ideas, solutions and lessons learned to:

• Accelerate your path from concept to product by applying insightful and relevant strategies from 80+ industry thought-leading speakers across 7 focused tracks >> Download the brochure 
• Stay at the forefront of innovation by evaluating new technologies and cutting-edge data in the exhibit and poster hall 
• Jump start collaborations and partnerships through networking luncheons, private exhibit hall tours, evening cocktail receptions, interactive panel discussions and more 

New! All registered attendees gain access to Attendee Connect, the networking tool to make connecting with new customers and partners easier than ever before.

"Cell and gene immunotherapies continue to develop at a rapid pace. IBC continues to grow with this promising field. I will be back in the future!" - Prentice Curry, VP of Quality & Operations, Kite Pharma

Share this article with your social network, just click below to share now!

Share |